Homologous prime-boost with Zika virus envelope protein and poly (I:C) induces robust specific humoral and cellular immune responses

Amaral, Marcelo Pires; Apostólico, Juliana de Souza; Tomita, Nádia; Coirada, Fernanda Caroline; Lunardelli, Victória Alves Santos; Fernandes, Edgar Ruz; Souza, Higo Fernando Santos; Astray, Renato Mancini; Boscardin, Sílvia Beatriz; Rosa, Daniela Santoro

doi:10.1016/j.vaccine.2020.03.037

Cited by 18 publications

(18 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, Poly (I:C) was a strong candidate since it not only mimics viral RNA and activates TLR3, but also matures dendritic cells and polarizes T cell responses to a Th1 profile ( Martins et al., 2015 ). In agreement with these findings, Poly (I:C) was also the best adjuvant to use with the recombinant Zika virus envelope protein (E ZIKV ) ( Amaral et al., 2020 ). Other adjuvants also induced robust humoral response using E2 CHIKV antigen.…”

Section: Discussionsupporting

confidence: 60%

Prime-boost with Chikungunya virus E2 envelope protein combined with Poly (I:C) induces specific humoral and cellular immune responses

Amaral

Coirada

Apostólico

et al. 2021

Current Research in Immunology

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 60%

Prime-boost with Chikungunya virus E2 envelope protein combined with Poly (I:C) induces specific humoral and cellular immune responses

Amaral

Coirada

Apostólico

et al. 2021

Current Research in Immunology

Self Cite

View full text Add to dashboard Cite

“…Many groups have reported that the compounds of this class activate mechanisms of immune response to various pathogens [40]. They are known to act as adjuvants during immunization by viral antigens [41,42], including the HCV E2 glycoprotein [43]. Therefore, this type of adjuvants was chosen in our study for the comparison of adjuvant properties of other, less studied compounds.…”

Section: Discussionmentioning

confidence: 99%

Difluoromethylornithine (DFMO), an Inhibitor of Polyamine Biosynthesis, and Antioxidant N-Acetylcysteine Potentiate Immune Response in Mice to the Recombinant Hepatitis C Virus NS5B Protein

Леснова

Масалова

Permyakova

et al. 2021

IJMS

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is one of the main triggers of chronic liver disease. Despite tremendous progress in the HCV field, there is still no vaccine against this virus. Potential vaccines can be based on its recombinant proteins. To increase the humoral and, especially, cellular immune response to them, more effective adjuvants are needed. Here, we evaluated a panel of compounds as potential adjuvants using the HCV NS5B protein as an immunogen. These compounds included inhibitors of polyamine biosynthesis and urea cycle, the mTOR pathway, antioxidants, and cellular receptors. A pronounced stimulation of cell proliferation and interferon-γ (IFN-γ) secretion in response to concanavalin A was shown for antioxidant N-acetylcysteine (NAC), polyamine biosynthesis inhibitor 2-difluoromethylornithine (DFMO), and TLR9 agonist CpG ODN 1826 (CpG). Their usage during the immunization of mice with the recombinant NS5B protein significantly increased antibody titers, enhanced lymphocyte proliferation and IFN-γ production. NAC and CpG decreased relative Treg numbers; CpG increased the number of myeloid-derived suppressor cells (MDSCs), whereas neither NAC nor DFMO affected MDSC counts. NAC and DFMO suppressed NO and interleukin 10 (IL-10) production by splenocytes, while DFMO increased the levels of IL-12. This is the first evidence of immunomodulatory activity of NAC and DFMO during prophylactic immunization against infectious diseases.

show abstract

“…This concern is also applied to ZIKV, which has extensive sequence homology with DENV. Several studies have repeatedly demonstrated that proper antigen/adjuvant choices can result in balanced humoral and cellular immune responses and confer protective immunity in mice and NHPs [ 40 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 219 ]. Altogether, these findings highlight the potential of these recombinant protein-based flavivirus vaccines toward translation into clinical studies.…”

Section: Discussionmentioning

confidence: 99%

“…Along the same line, Amaral et al compared a subunit vaccine based on the ZIKV E protein produced in E. coli (adjuvanted with poly (I:C) or CpG ODN) to a DNA vaccine (pVAX-E ZIKV ) encoding the same antigen in homologous and heterologous prime-boost immunization regimens [ 219 ]. Their findings showed that mice immunized with one dose of E-poly (I:C) promoted a robust humoral response with a slightly increase after a booster dose and that mice immunized with E-CpG ODN required three doses to reach a similar antibody level.…”

Section: Zika Virusmentioning

confidence: 99%

“…The homologous prime-boost immunization with E-poly (I:C) induced a stronger humoral response when compared to mice immunized with homologous pVAX-E ZIKV or heterologous pVAX-E ZIKV + E-poly (I:C) prime-boost regimens. The highest cellular response was detected in mice submitted to homologous E-poly (I:C) and heterologous pVAX-E ZIKV + E-poly (I:C) prime-boost immunization regimens [ 219 ].…”

Section: Zika Virusmentioning

confidence: 99%

See 1 more Smart Citation

Anti-Flavivirus Vaccines: Review of the Present Situation and Perspectives of Subunit Vaccines Produced in Escherichia coli

et al. 2020

View full text Add to dashboard Cite

This article aims to review the present status of anti-flavivirus subunit vaccines, both those at the experimental stage and those already available for clinical use. Aspects regarding development of vaccines to Yellow Fever virus, (YFV), Dengue virus (DENV), West Nile virus (WNV), Zika virus (ZIKV), and Japanese encephalitis virus (JEV) are highlighted, with particular emphasis on purified recombinant proteins generated in bacterial cells. Currently licensed anti-flavivirus vaccines are based on inactivated, attenuated, or virus-vector vaccines. However, technological advances in the generation of recombinant antigens with preserved structural and immunological determinants reveal new possibilities for the development of recombinant protein-based vaccine formulations for clinical testing. Furthermore, novel proposals for multi-epitope vaccines and the discovery of new adjuvants and delivery systems that enhance and/or modulate immune responses can pave the way for the development of successful subunit vaccines. Nonetheless, advances in this field require high investments that will probably not raise interest from private pharmaceutical companies and, therefore, will require support by international philanthropic organizations and governments of the countries more severely stricken by these viruses.

show abstract

Homologous prime-boost with Zika virus envelope protein and poly (I:C) induces robust specific humoral and cellular immune responses

Cited by 18 publications

References 55 publications

Prime-boost with Chikungunya virus E2 envelope protein combined with Poly (I:C) induces specific humoral and cellular immune responses

Prime-boost with Chikungunya virus E2 envelope protein combined with Poly (I:C) induces specific humoral and cellular immune responses

Difluoromethylornithine (DFMO), an Inhibitor of Polyamine Biosynthesis, and Antioxidant N-Acetylcysteine Potentiate Immune Response in Mice to the Recombinant Hepatitis C Virus NS5B Protein

Anti-Flavivirus Vaccines: Review of the Present Situation and Perspectives of Subunit Vaccines Produced in Escherichia coli

Contact Info

Product

Resources

About